Atea Pharmaceuticals Inc (AVIR) (Q3 2026) Earnings Call Highlights: $200 Million Credit ...
Atea Pharmaceuticals Inc (AVIR) reported $191.2 million in cash, secured a $200 million credit facility to fund its BEM/RUZASVIR commercial launch without equity dilution, and highlighted a 94% SVR Related Stocks: AVIR ,